News

Febuxostat, a non-purine selective inhibitor of xanthine oxidase is used to treat chronic hyperuricemia in gout patients. Teijin Pharma signed a licensing agreement with SK Chemicals in July

SEBVI Technology uses Epstein Barr Virus for immortalizing and isolating circulating human B cells from the blood of immunocompetent individuals which secrete antigen-specific IgG antibodies. PX’T plans to

The Phase 3 trial which aims at over all survival, is a double-blind, randomized trial involved around 430 patients to compare the safety and efficacy of perifosine +

Currently, mipomersen is in late-stage development for the reduction of LDL cholesterol (LDL-C). Genzyme and Isis Pharma said that if approved the drug will be marketed under Kynamro

The joint venture which will focus on developing, manufacturing and promoting generic drugs, will be 51% owned by Fujifilm and 49% by the Indian drug maker. The new

Chasse-sur-Rhone provides for process scale-ups, the supply of clinical batches and the regular production of low volume compounds under cGMP. Freeport site performs custom manufacturing services from late

The tie up allows Ironwood to develop and commercialize the product, however Depomed will help in initial product formulation. As per the terms of the deal, Depomed is

Mylan‘s net earnings were $146.99m, compared to $86.93m for the same period in the prior year. The company has posted earnings from operations as $280.47m for the second

Genedata Expressionist for MS processes large experimental data sets of GC- and LC-MS (/MS), labeled and unlabeled – regardless of data formats. Each technology workflow requires specific pre-processing